Multi-gene panel testing confirms phenotypic variability in MUTYH-Associated Polyposis

被引:27
|
作者
Sutcliffe, Erin G. [1 ]
Thompson, Amanda Bartenbaker [1 ]
Stettner, Amy R. [2 ]
Marshall, Megan L. [1 ]
Roberts, Maegan E. [1 ]
Susswein, Lisa R. [1 ]
Wang, Ying [1 ]
Klein, Rachel T. [2 ]
Hruska, Kathleen S. [1 ]
Solomon, Benjamin D. [1 ]
机构
[1] GeneDx, 207 Perry Pkwy, Gaithersburg, MD 20877 USA
[2] My Gene Team, Miami, FL USA
关键词
Inherited cancer; Genetic testing; MAP; MUTYH; FAP; EXCISION-REPAIR GENE; COLORECTAL-CANCER; ADENOMATOUS POLYPOSIS; MYH MUTATIONS; PREVALENCE; RISK; CARRIERS; SUSCEPTIBILITY; FAMILY;
D O I
10.1007/s10689-018-00116-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Biallelic pathogenic variants (PVs) in MUTYH cause MUTYH-Associated Polyposis (MAP), which displays phenotypic overlap with other hereditary colorectal cancer (CRC) syndromes including Familial Adenomatous Polyposis (FAP) and Lynch syndrome. We report the phenotypic spectrum of MAP in the context of multi-gene hereditary cancer panel testing. Genetic testing results and clinical histories were reviewed for individuals with biallelic MUTYH PVs detected by panel testing at a single commercial molecular diagnostic laboratory. Biallelic MUTYH PVs were identified in 82 individuals (representing 0.2% of tested individuals) with most (75/82; 91.5%) reporting a personal history of CRC and/or polyps. Ten percent (6/61) of individuals reporting polyp number reported fewer than 10 polyps and therefore did not meet current MAP testing criteria. Extracolonic cancers (21/82; 25.6%), multiple primaries (19/82; 23.2%), Lynch-like (17/82; 20.7%) and FAP-like phenotypes (16/82; 19.5%) were observed, including individuals with mismatch repair-deficient tumors (3/82; 3.7%), sebaceous neoplasms (2/82; 2.4%), or congenital hypertrophy of the retinal pigment epithelium (CHRPE) (2/82; 2.4%). We report what is to our knowledge the first cohort of individuals with MAP identified by panel testing. The phenotypic spectrum of MAP observed in this cohort aligns with the published literature. In addition to standard indications for MUTYH testing, our data provide evidence to support consideration of MAP in the differential diagnosis for some individuals with fewer than 10 polyps, depending on other personal and/or family history, as well as for individuals suspected to have Lynch syndrome or FAP.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [41] A plausible normal polymorphism of MUTYH splicing variant detected through multi-gene cancer panel testing
    Yamamoto, Rie
    Nishisaka, Takashi
    Hattori, Yui
    Doi, Mihoko
    Shinozaki, Katsunori
    Ishikawa, Nobuhisa
    Yamamoto, Hideki
    Hirasawa, Akira
    Hara, Tetsuaki
    Itamoto, Toshiyuki
    CANCER SCIENCE, 2021, 112 : 663 - 663
  • [42] Papillary thyroid cancer in a patient with MUTYH-associated polyposis (MAP)
    Muhammad Ali Pervaiz
    Amanda Eppolito
    Karen Schmidt
    Familial Cancer, 2010, 9 : 595 - 597
  • [43] MUTYH-ASSOCIATED POLYPOSIS: IS TIME TO CHANGE UPPER GI SURVEILLANCE?
    Sanchez-Mete, L.
    Casadio, M.
    Martayan, A.
    Stigliano, V
    DIGESTIVE AND LIVER DISEASE, 2022, 54 : S127 - S128
  • [44] The impact of chromoendoscopy for surveillance of the duodenum in patients with MUTYH-associated polyposis and familial adenomatous polyposis
    Hurley, Joanna J.
    Thomas, Laura E.
    Walton, Sarah-Jane
    Thomas-Gibson, Siwan
    Haycock, Adam
    Suzuki, Noriko
    Mort, Matthew
    Williams, Geraint
    Morgan, Meleri
    Clark, Susan K.
    Sampson, Julian R.
    Dolwani, Sunil
    GASTROINTESTINAL ENDOSCOPY, 2018, 88 (04) : 665 - 673
  • [45] Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum
    Villy, Marie-Charlotte
    Masliah-Planchon, Julien
    Buecher, Bruno
    Beaulaton, Clement
    Vincent-Salomon, Anne
    Stoppa-Lyonnet, Dominique
    Colas, Chrystelle
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2022, 65 (01)
  • [46] Do NSAIDs suppress polyps in MUTYH-associated polyposis? A case report
    Duveen Sturgeon
    Alan J Herline
    Paul E Wise
    Hereditary Cancer in Clinical Practice, 9 (Suppl 1)
  • [47] Clinical and Histopathologic Characterization of Polyp Burden in Patients With MUTYH-Associated Polyposis
    Wiland, Homer
    Kalady, Matthew
    Heald, Brandie
    LaGuardia, Lisa
    Pai, Rish
    MODERN PATHOLOGY, 2015, 28 : 198A - 198A
  • [48] Genomic analysis of pancreatic ductal adenocarcinoma in a patient with MUTYH-associated polyposis
    Schrader, Kasmintan A.
    Chu'ng, Carolyn
    Zhao, Eric
    Wong, Hui-li
    Shen, Yaoqing
    Jones, Martin
    Thomson, Tom
    Lim, Howard
    Young, Sean
    Cremin, Carol
    Holt, Robert
    Eirew, Peter
    Karasinska, Joanna
    Schein, Jacquie
    Zhao, Yongjun
    Mungall, Andy
    Moore, Richard
    Ma, Yussanne
    Fok, Alexandra
    Roscoe, Robyn
    Yip, Stephen
    Mitchell, Gillian
    Karsan, Aly
    Jones, Steven
    Schaeffer, David
    Laskin, Janessa
    Marra, Marco
    Renouf, Daniel
    CANCER RESEARCH, 2016, 76
  • [49] Multi-gene panel testing of melanoma patients
    Russo, Alessia
    Ogliara, Paola
    Catalano, Chiara
    Restivo, Francesca
    Vignolo, Francesca
    Birolo, Giovanni
    Palermo, Flavia
    Bracco, Cecilia
    Fiorito, Debora
    D'Alessio, Francesca
    Cavalchini, Guido Casalis
    Grosso, Enrico
    Maffe, Antonella
    Ungari, Silvana
    Colombo, Enrico
    Marchio, Caterina
    Quaglino, Pietro
    Ribero, Simone
    Matullo, Giuseppe
    Pasini, Barbara
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 534 - 535
  • [50] High frequency of copy neutral LOH in MUTYH-associated polyposis carcinomas
    Middeldorp, A.
    Van Puijenbroek, M.
    Nielsen, M.
    Corver, W. E.
    Jordanova, E. S.
    Tops, C. M. J.
    Vasen, H. F. A.
    Hes, F. J.
    van Wezel, T.
    Morreau, H.
    EJC SUPPLEMENTS, 2008, 6 (09): : 114 - 115